Heyholder
‹ Activism Filings

ABL Bio Inc. Q3 operating loss of KRW 19.9 billion on revenue of KRW 8.8 billion

ABL Bio Inc.· Periodic Report

AI summary · Not investment advice

ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.

Operating profit · 3 months

KRW -19.9 billion

Key facts

Revenue (3 months)
KRW 8.8 billion
Net income (3 months)
KRW -24.6 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 1.4 billion
Revenue (year to date)
KRW 41.6 billion
Operating profit (prior-year 3 months)
KRW -22.4 billion
Operating profit (year to date)
KRW -53.9 billion
Net income (prior-year 3 months)
KRW -21.3 billion
Net income (year to date)
KRW -54.3 billion

Commentary

AI commentary · Not investment advice

What happened

ABL Bio filed its quarterly report for the third quarter of 2026. The figures are on a consolidated basis, and the cumulative period runs from January 1 to September 30.

In the company's terms

Sales for the latest 3 months were KRW 8.76 billion. That compares with KRW 1.44 billion a year earlier, a change of +506.8%. Cumulative sales this year were KRW 41.60 billion.

What changes for shareholders

Operating profit (profit from the core business) for the latest 3 months was KRW -19.91 billion. A year earlier it was KRW -22.41 billion. Cumulative operating profit this year was KRW -53.94 billion.

Net income (the final profit after all costs and taxes) for the latest 3 months was KRW -24.62 billion. A year earlier it was KRW -21.30 billion. Cumulative net income this year was KRW -54.29 billion.

Comments

No comments yet

Comments from shareholders will appear here.